Lexaria Bioscience: Patented Oral Drug Delivery System

Working to improve the lives of millions

Lexaria Bioscience’s proprietary drug delivery technology is DehydraTECH™. It improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier delivery methods as well as increasing the effectiveness of fat-soluble active molecules and drugs.

The company’s technology can be applied to many different drugs and other active ingredients such as; vitamins in oral formats including tablets,  capsules, oral suspensions – and even foods, beverages and topical preparations.

DehydraTECH™ increases bio-absorption by up to 5x and reduces the time of onset from up to 1 – 2 hours to just minutes. Additionally, it masks unwanted tastes and can reduce unwanted side effects by enabling lower overall dosing.

Companies with operations in over 100 countries around the world are examining DehydraTECH for possible use in the smokeless tobacco-derived nicotine industry, in the health and wellness industry, and more. Moreover, this patented technology is highly scalable and is currently under study for use with antiviral drugs – for diseases like Covid 19, potential new and improved hypertension medicines and oral nicotine.

Each of these applications represents a multi-billion dollar market and exceptional opportunities.

For more information on Lexaria Bioscience Corp. ( NASDAQ: LEXX, CSE: LXX) please click the request investor info button.

Request Investor Info